NO20064854L - Anvendelse av anti-CTLA-4-antistoffer - Google Patents

Anvendelse av anti-CTLA-4-antistoffer

Info

Publication number
NO20064854L
NO20064854L NO20064854A NO20064854A NO20064854L NO 20064854 L NO20064854 L NO 20064854L NO 20064854 A NO20064854 A NO 20064854A NO 20064854 A NO20064854 A NO 20064854A NO 20064854 L NO20064854 L NO 20064854L
Authority
NO
Norway
Prior art keywords
ctla
antibody
stem cell
treatment
cancer
Prior art date
Application number
NO20064854A
Other languages
English (en)
Norwegian (no)
Inventor
Dennis Alan Noe
Duglas Charles Hanson
Elleen Elliott Mueller
Jesus Gomez-Navarro
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20064854L publication Critical patent/NO20064854L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20064854A 2004-03-26 2006-10-25 Anvendelse av anti-CTLA-4-antistoffer NO20064854L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55680104P 2004-03-26 2004-03-26
PCT/IB2005/000671 WO2005092380A2 (en) 2004-03-26 2005-03-14 Uses of anti-ctla-4 antibodies

Publications (1)

Publication Number Publication Date
NO20064854L true NO20064854L (no) 2006-12-22

Family

ID=35056778

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064854A NO20064854L (no) 2004-03-26 2006-10-25 Anvendelse av anti-CTLA-4-antistoffer

Country Status (15)

Country Link
US (1) US20050226875A1 (pt)
EP (1) EP1732600A2 (pt)
JP (1) JP2007530526A (pt)
KR (1) KR100845354B1 (pt)
CN (1) CN1964739A (pt)
AR (1) AR049480A1 (pt)
AU (1) AU2005225227A1 (pt)
BR (1) BRPI0509274A (pt)
CA (1) CA2560919A1 (pt)
IL (1) IL177602A0 (pt)
NO (1) NO20064854L (pt)
RU (1) RU2346702C2 (pt)
TW (2) TW200829271A (pt)
WO (1) WO2005092380A2 (pt)
ZA (1) ZA200607544B (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1863532A1 (en) * 2005-03-23 2007-12-12 Pfizer Products Incorporated Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
US20080279865A1 (en) * 2005-03-23 2008-11-13 Pfizer, Inc., Pfizer Products, Inc. Therapy of Prostate Cancer With Ctla-4 Antibodies and Hormonal Therapy
WO2006105488A2 (en) 2005-03-31 2006-10-05 Agensys, Inc. Antibodies and related molecules that bind to 161p2f10b proteins
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US9738872B2 (en) 2008-10-30 2017-08-22 Yeda Research And Development Co. Ltd. Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
PT2769737T (pt) * 2009-07-20 2017-06-29 Bristol Myers Squibb Co Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
JP6046494B2 (ja) 2010-02-08 2016-12-14 アジェンシス,インコーポレイテッド 161p2f10bタンパク質に結合する抗体薬物コンジュゲート(adc)
CA2810632C (en) 2010-09-08 2020-06-02 Yeda Research And Development Co. Ltd. Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
CA2810631A1 (en) * 2010-09-08 2012-03-15 Yeda Research And Development Co. Ltd. An immunosuppressive drug combination for a stable and long term engraftment
EP2621526B1 (en) 2010-09-29 2018-06-06 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins
WO2013013029A1 (en) 2011-07-19 2013-01-24 The Board Of Trustees Of The University Of Illinois Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes
CN103930130B (zh) 2011-09-08 2016-07-06 耶达研究及发展有限公司 抗第三方中央型记忆t细胞、其产生方法以及其在移植和疾病治疗中的应用
JP6434905B2 (ja) 2012-05-04 2018-12-05 ファイザー・インク 前立腺関連抗原およびワクチンに基づく免疫療法レジメン
TR201900694T4 (tr) 2012-08-23 2019-02-21 Agensys Inc 158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc).
KR20160060634A (ko) 2013-08-01 2016-05-30 어젠시스 인코포레이티드 Cd37 단백질에 결합하는 항체 약물 컨쥬게이트(adc)
US10155818B2 (en) 2014-05-28 2018-12-18 Agenus Inc. Anti-GITR antibodies and methods of use thereof
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
AU2015330731B2 (en) 2014-10-10 2020-07-09 Idera Pharmaceuticals, Inc. Treatment of cancer using TLR9 agonist with checkpoint inhibitors
JP6917902B2 (ja) * 2015-02-13 2021-08-11 ソレント・セラピューティクス・インコーポレイテッド Ctla4に結合する抗体医薬
TWI719967B (zh) 2015-03-09 2021-03-01 美商艾澤西公司 結合至flt3蛋白之抗體藥物結合物(adc)
AU2016271591A1 (en) 2015-05-29 2017-12-21 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
CN108135938A (zh) 2015-07-16 2018-06-08 耶达研究及发展有限公司 基因修饰的抗第三方中央型记忆t细胞及其在免疫疗法中的用途
RU2619208C2 (ru) * 2015-10-08 2017-05-12 ДИАМОНДЗЛИТЕ ЛИМИТЕД Тридент Чамберс Способ профилактического лечения при развитии неопластических процессов кожной ткани, таких как меланома, базально-клеточный рак, плоскоклеточный рак
JP7089470B2 (ja) 2015-12-02 2022-06-22 アジェナス インコーポレイテッド 抗体およびその使用方法
MX2018011204A (es) 2016-03-15 2019-03-07 Mersana Therapeutics Inc Conjugados de anticuerpo-farmaco dirigidos a napi2b y sus metodos de uso.
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
EA201991383A1 (ru) 2016-12-07 2019-12-30 Эйдженус Инк. Антитела против ctla-4 и способы их применения
EP3571295A1 (en) 2017-01-18 2019-11-27 Yeda Research and Development Co. Ltd Genetically modified veto cells and use of same in immunotherapy
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
WO2018160538A1 (en) 2017-02-28 2018-09-07 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
MX2020003132A (es) 2017-09-21 2020-07-28 Eucure Beijing Biopharma Co Ltd Anticuerpos anti-ctla4 y usos de los mismos.
US11638760B2 (en) 2017-11-27 2023-05-02 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CA3085861C (en) * 2017-12-20 2023-09-26 Harbour Biomed (Shanghai) Co., Ltd Antibodies binding ctla-4 and uses thereof
US20220305127A1 (en) 2017-12-21 2022-09-29 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
JP2021508477A (ja) 2017-12-29 2021-03-11 オンコラス, インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
US20200399348A1 (en) * 2018-02-20 2020-12-24 Emory University HPV Proteins, Antibodies, and Uses in Managing Abnormal Epithelial Cell Growth
MX2021004906A (es) 2018-10-29 2021-09-10 Mersana Therapeutics Inc Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos.
AU2020258384A1 (en) 2019-04-15 2021-11-04 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer
WO2021066869A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
CA3176356A1 (en) 2020-04-22 2021-10-28 Anne BROOKS Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
EP4225792A1 (en) 2020-10-08 2023-08-16 Affimed GmbH Trispecific binders
AU2022292462A1 (en) 2021-06-18 2023-12-07 Nammi Therapeutics, Inc. FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF
WO2023007023A1 (en) 2021-07-30 2023-02-02 Affimed Gmbh Duplexbodies
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP3793693B2 (ja) * 1998-12-23 2006-07-05 ファイザー インコーポレーテッド Ctla−4に対するヒトモノクローナル抗体
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
MXPA04010013A (es) * 2002-04-12 2004-12-13 Medarex Inc Metodos de tratamiento utilizando anticuerpos al antigeno-4 asociado con el linfocito t citotoxico.

Also Published As

Publication number Publication date
RU2006134045A (ru) 2008-03-27
AR049480A1 (es) 2006-08-09
US20050226875A1 (en) 2005-10-13
TW200829271A (en) 2008-07-16
RU2346702C2 (ru) 2009-02-20
CA2560919A1 (en) 2005-10-06
JP2007530526A (ja) 2007-11-01
IL177602A0 (en) 2006-12-10
AU2005225227A1 (en) 2005-10-06
EP1732600A2 (en) 2006-12-20
WO2005092380A2 (en) 2005-10-06
CN1964739A (zh) 2007-05-16
WO2005092380A3 (en) 2006-06-15
KR100845354B1 (ko) 2008-07-09
TW200602078A (en) 2006-01-16
ZA200607544B (en) 2008-07-30
BRPI0509274A (pt) 2007-09-04
KR20070007114A (ko) 2007-01-12

Similar Documents

Publication Publication Date Title
NO20064854L (no) Anvendelse av anti-CTLA-4-antistoffer
Hosoyama et al. Intravenously injected human multilineage-differentiating stress-enduring cells selectively engraft into mouse aortic aneurysms and attenuate dilatation by differentiating into multiple cell types
MX2009004238A (es) Metodos y composiciones para tratamiento de defectos oseos con poblaciones de celulas de placenta.
You et al. Comparative analysis of periprostatic implantation and intracavernosal injection of human adipose tissue‐derived stem cells for erectile function recovery in a rat model of cavernous nerve injury
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2007035843A3 (en) Methods and compositions for organ and tissue functionality
SV2006002258A (es) Inmunoterapia de trastornos autoinmunes
WO2007056539A3 (en) Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
GEP20125476B (en) Compositions of antibodies of dickkopf-1 and use thereof
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
ECSP055635A (es) Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico
NO20083793L (no) Antistoffer mot amyloid-beta peptid
WO2007084775A3 (en) Compositions and methods for modulation of suppressor t cell activation
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
EA200701600A1 (ru) Способ получения лёгкодоступного клеточного материала из периферической крови и композиция на его основе
WO2008096268A3 (en) Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery
MX2021009626A (es) Metodos y composiciones para el tratamiento de gastritis de celulas cebadas, esofagitis de celulas cebadas, enteritis de celulas cebadas, duodenitis de celulas cebadas y/o gastroenteritis de celulas cebadas.
Xu et al. Defocused low-energy shock wave activates adipose tissue-derived stem cells in vitro via multiple signaling pathways
MX2021012041A (es) Metodos para promover la diferenciacion de celulas epiteliales timicas y progenitores de celulas epiteliales timicas de celulas madre pluripotentes, celulas resultantes y usos de estas.
WO2021168119A3 (en) Methods and compositions for identifying and treating subjects at risk of poor cancer survival
CR20220465A (es) Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos
WO2006093860A3 (en) Method and composition for repairing heart tissue
Yang et al. Co‐overexpression of VEGF and GDNF in adipose‐derived stem cells optimizes therapeutic effect in neurogenic erectile dysfunction model
Pakpahan et al. Stem cell therapy and diabetic erectile dysfunction: a critical review
MX2019013137A (es) Metodos y composiciones para tratar enfermedades oculares alergicas.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application